CCA
NBRV

Catalyst Capital Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Catalyst Capital Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2
Closed -$4K – 667
2015
Q4 		$4K Buy
+2
New +$4.88K ﹤0.01% 476

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Catalyst Capital Advisors's NBRV Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2016, closing a stake of 2 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in NBRV in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 20 funds tracked by Wall St. Rank hold NBRV as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 2 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2016, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $4K in Q4 2015.
  • 20 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.